Novartis’ pelacarsen failed a widely watched seven-year trial aimed at lowering lipoprotein(a) and reducing heart attack or stroke risk, according to reporting summarized by STAT+. The setback arrives after long expectations for first-in-class Lp(a) lowering to reshape cardiovascular prevention. The article frames the results as a potential industry-wide re-rating point for other teams pursuing Lp(a) assets, many of which have invested heavily in the same mechanism class. For biotech strategy teams, the immediate takeaway is not only the failed endpoint but the signal to investors and developers that cardiovascular development—especially outcome-driven studies—remains highly sensitive to effect size and statistical durability even when biology looks compelling.